Trump FDA Official Warns Recent Changes at Agency Risk Public Health: Report

Dr. Richard Pazdur, appointed Nov. 11 as the FDA’s chief drug regulator, has privately warned that Commissioner Marty Makary’s rapid reforms—including proposals to rely on a single study for certain approvals, reduce study requirements for label changes, and fast-track a program to shorten review times for priority treatments—could pose public-health risks and raise legal and transparency concerns. Pazdur also pushed back against efforts to sideline career scientists from reviews of antidepressants, puberty blockers and psychedelics, saying their involvement is essential; his objections come amid agency layoffs, the abrupt resignation of his predecessor and industry complaints that FDA decisions have become erratic and unpredictable, creating uncertainty for patients and companies. Both officials have publicly defended their work.

Analysis

Dr. Richard Pazdur, appointed Nov. 11 as the FDA's top drug regulator, has privately warned that Commissioner Marty Makary's rapid reforms — including moving toward reliance on a single study for some approvals, reducing study requirements for label changes, and a Trump-supported program to significantly shorten review times for priority treatments — "pose a risk to public health" and raise concerns about the "legality and pace" of changes. Pazdur flagged that the priority-review program is insufficiently transparent and "could be illegal," and he objected to efforts to sideline career scientists from reviews of antidepressants, puberty blockers and psychedelics, arguing their involvement is essential for safety and transparency. The warnings arrive amid agency layoffs, the abrupt resignation of Pazdur's predecessor and industry complaints that FDA decisions have become "erratic and unpredictable... creating uncertainty for patients," signaling elevated operational and legal risk at the agency. Both officials have publicly defended their roles and Makary has called Pazdur "a true regulatory innovator," indicating reforms are contested but may continue, which implies sustained policy and timing uncertainty for drug approvals and label-change processes.

Key Decisions for Investors

• Reassess event-driven exposure to small-cap biotechs with near-term approval readouts or label-change catalysts and consider reducing position sizes or buying protective puts
• Avoid paying valuation premia for companies whose programs depend on expedited pathways until the legality, transparency and implementation details are clarified
• Monitor FDA communications, staffing changes, and any legal challenges to the priority-review program as leading indicators for approval-timing risk and rerate potential
• Trim or hedge exposure to firms developing antidepressants, puberty-blocker, or psychedelic therapeutics until career-scientist involvement and review standards are resolved
• Favor larger, diversified healthcare names with broader revenue streams that are less sensitive to single-approval timing and regulatory-process volatility